nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—SIGMAR1—Tamoxifen—pancreatic cancer	0.526	1	CbGbCtD
Phentolamine—Oral pain—Sunitinib—pancreatic cancer	0.0148	0.0539	CcSEcCtD
Phentolamine—NISCH—Paclitaxel—Docetaxel—pancreatic cancer	0.0123	1	CbGdCrCtD
Phentolamine—Peptic ulcer—Erlotinib—pancreatic cancer	0.00666	0.0243	CcSEcCtD
Phentolamine—Oral pain—Epirubicin—pancreatic cancer	0.00567	0.0207	CcSEcCtD
Phentolamine—Oral pain—Doxorubicin—pancreatic cancer	0.00525	0.0191	CcSEcCtD
Phentolamine—Tenderness—Tamoxifen—pancreatic cancer	0.00516	0.0188	CcSEcCtD
Phentolamine—Tenderness—Erlotinib—pancreatic cancer	0.0051	0.0186	CcSEcCtD
Phentolamine—Blood pressure increased—Sunitinib—pancreatic cancer	0.00385	0.0141	CcSEcCtD
Phentolamine—Tenderness—Gemcitabine—pancreatic cancer	0.00354	0.0129	CcSEcCtD
Phentolamine—Tenderness—Fluorouracil—pancreatic cancer	0.00349	0.0127	CcSEcCtD
Phentolamine—Injection site reaction—Gemcitabine—pancreatic cancer	0.00307	0.0112	CcSEcCtD
Phentolamine—Nasal congestion—Sunitinib—pancreatic cancer	0.00307	0.0112	CcSEcCtD
Phentolamine—Angina pectoris—Tamoxifen—pancreatic cancer	0.00275	0.01	CcSEcCtD
Phentolamine—Abdominal pain upper—Sunitinib—pancreatic cancer	0.00256	0.00932	CcSEcCtD
Phentolamine—Acute coronary syndrome—Tamoxifen—pancreatic cancer	0.00248	0.00905	CcSEcCtD
Phentolamine—Myocardial infarction—Tamoxifen—pancreatic cancer	0.00247	0.009	CcSEcCtD
Phentolamine—Acute coronary syndrome—Erlotinib—pancreatic cancer	0.00246	0.00896	CcSEcCtD
Phentolamine—Myocardial infarction—Erlotinib—pancreatic cancer	0.00244	0.00891	CcSEcCtD
Phentolamine—Blood pressure increased—Docetaxel—pancreatic cancer	0.00219	0.00801	CcSEcCtD
Phentolamine—Injection site reaction—Docetaxel—pancreatic cancer	0.00218	0.00796	CcSEcCtD
Phentolamine—Acute coronary syndrome—Sunitinib—pancreatic cancer	0.00213	0.00775	CcSEcCtD
Phentolamine—Orthostatic hypotension—Irinotecan—pancreatic cancer	0.00211	0.00768	CcSEcCtD
Phentolamine—Flushing—Tamoxifen—pancreatic cancer	0.0021	0.00765	CcSEcCtD
Phentolamine—Arrhythmia—Tamoxifen—pancreatic cancer	0.00202	0.00736	CcSEcCtD
Phentolamine—Mediastinal disorder—Erlotinib—pancreatic cancer	0.00202	0.00735	CcSEcCtD
Phentolamine—Arrhythmia—Erlotinib—pancreatic cancer	0.002	0.00729	CcSEcCtD
Phentolamine—Bradycardia—Sunitinib—pancreatic cancer	0.00197	0.00719	CcSEcCtD
Phentolamine—Angina pectoris—Irinotecan—pancreatic cancer	0.00194	0.00708	CcSEcCtD
Phentolamine—Angina pectoris—Fluorouracil—pancreatic cancer	0.00186	0.00678	CcSEcCtD
Phentolamine—Injection site pain—Epirubicin—pancreatic cancer	0.00181	0.00661	CcSEcCtD
Phentolamine—Flushing—Sunitinib—pancreatic cancer	0.0018	0.00655	CcSEcCtD
Phentolamine—Cardiac disorder—Sunitinib—pancreatic cancer	0.0018	0.00655	CcSEcCtD
Phentolamine—Angiopathy—Sunitinib—pancreatic cancer	0.00176	0.00641	CcSEcCtD
Phentolamine—Acute coronary syndrome—Irinotecan—pancreatic cancer	0.00175	0.00639	CcSEcCtD
Phentolamine—Mediastinal disorder—Sunitinib—pancreatic cancer	0.00174	0.00636	CcSEcCtD
Phentolamine—Myocardial infarction—Irinotecan—pancreatic cancer	0.00174	0.00635	CcSEcCtD
Phentolamine—Arrhythmia—Sunitinib—pancreatic cancer	0.00173	0.00631	CcSEcCtD
Phentolamine—Acute coronary syndrome—Gemcitabine—pancreatic cancer	0.00171	0.00622	CcSEcCtD
Phentolamine—Hypertension—Tamoxifen—pancreatic cancer	0.0017	0.0062	CcSEcCtD
Phentolamine—Myocardial infarction—Gemcitabine—pancreatic cancer	0.0017	0.00619	CcSEcCtD
Phentolamine—Injection site pain—Doxorubicin—pancreatic cancer	0.00168	0.00612	CcSEcCtD
Phentolamine—Acute coronary syndrome—Fluorouracil—pancreatic cancer	0.00168	0.00612	CcSEcCtD
Phentolamine—Chest pain—Tamoxifen—pancreatic cancer	0.00167	0.00611	CcSEcCtD
Phentolamine—Myocardial infarction—Fluorouracil—pancreatic cancer	0.00167	0.00608	CcSEcCtD
Phentolamine—Chest pain—Erlotinib—pancreatic cancer	0.00166	0.00604	CcSEcCtD
Phentolamine—Bradycardia—Irinotecan—pancreatic cancer	0.00162	0.00592	CcSEcCtD
Phentolamine—Nervous system disorder—Erlotinib—pancreatic cancer	0.00156	0.00568	CcSEcCtD
Phentolamine—Cardiac disorder—Irinotecan—pancreatic cancer	0.00148	0.0054	CcSEcCtD
Phentolamine—Flushing—Irinotecan—pancreatic cancer	0.00148	0.0054	CcSEcCtD
Phentolamine—Injection site reaction—Epirubicin—pancreatic cancer	0.00147	0.00537	CcSEcCtD
Phentolamine—Abdominal pain upper—Docetaxel—pancreatic cancer	0.00146	0.00531	CcSEcCtD
Phentolamine—Orthostatic hypotension—Docetaxel—pancreatic cancer	0.00146	0.00531	CcSEcCtD
Phentolamine—Hypertension—Sunitinib—pancreatic cancer	0.00145	0.00531	CcSEcCtD
Phentolamine—Angiopathy—Irinotecan—pancreatic cancer	0.00145	0.00528	CcSEcCtD
Phentolamine—Paraesthesia—Tamoxifen—pancreatic cancer	0.00144	0.00526	CcSEcCtD
Phentolamine—Cardiac disorder—Gemcitabine—pancreatic cancer	0.00144	0.00526	CcSEcCtD
Phentolamine—Mediastinal disorder—Irinotecan—pancreatic cancer	0.00144	0.00524	CcSEcCtD
Phentolamine—Chest pain—Sunitinib—pancreatic cancer	0.00143	0.00523	CcSEcCtD
Phentolamine—Arrhythmia—Irinotecan—pancreatic cancer	0.00142	0.0052	CcSEcCtD
Phentolamine—Angiopathy—Gemcitabine—pancreatic cancer	0.00141	0.00514	CcSEcCtD
Phentolamine—Mediastinal disorder—Gemcitabine—pancreatic cancer	0.0014	0.00511	CcSEcCtD
Phentolamine—Arrhythmia—Gemcitabine—pancreatic cancer	0.00139	0.00506	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00139	0.00506	CcSEcCtD
Phentolamine—Pain—Tamoxifen—pancreatic cancer	0.00137	0.00501	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00137	0.005	CcSEcCtD
Phentolamine—Arrhythmia—Fluorouracil—pancreatic cancer	0.00136	0.00498	CcSEcCtD
Phentolamine—Injection site reaction—Doxorubicin—pancreatic cancer	0.00136	0.00497	CcSEcCtD
Phentolamine—Pain—Erlotinib—pancreatic cancer	0.00136	0.00496	CcSEcCtD
Phentolamine—Nervous system disorder—Sunitinib—pancreatic cancer	0.00135	0.00492	CcSEcCtD
Phentolamine—Angina pectoris—Docetaxel—pancreatic cancer	0.00134	0.00489	CcSEcCtD
Phentolamine—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00131	0.00479	CcSEcCtD
Phentolamine—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.0013	0.00474	CcSEcCtD
Phentolamine—Abdominal pain—Tamoxifen—pancreatic cancer	0.00127	0.00463	CcSEcCtD
Phentolamine—Abdominal pain—Erlotinib—pancreatic cancer	0.00126	0.00458	CcSEcCtD
Phentolamine—Paraesthesia—Sunitinib—pancreatic cancer	0.00123	0.0045	CcSEcCtD
Phentolamine—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.00121	0.00441	CcSEcCtD
Phentolamine—Myocardial infarction—Docetaxel—pancreatic cancer	0.0012	0.00439	CcSEcCtD
Phentolamine—Hypertension—Irinotecan—pancreatic cancer	0.0012	0.00437	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00119	0.00433	CcSEcCtD
Phentolamine—Pain—Sunitinib—pancreatic cancer	0.00118	0.00429	CcSEcCtD
Phentolamine—Hypertension—Gemcitabine—pancreatic cancer	0.00117	0.00426	CcSEcCtD
Phentolamine—Asthenia—Tamoxifen—pancreatic cancer	0.00115	0.0042	CcSEcCtD
Phentolamine—Chest pain—Gemcitabine—pancreatic cancer	0.00115	0.0042	CcSEcCtD
Phentolamine—Asthenia—Erlotinib—pancreatic cancer	0.00114	0.00416	CcSEcCtD
Phentolamine—Pruritus—Tamoxifen—pancreatic cancer	0.00114	0.00414	CcSEcCtD
Phentolamine—Chest pain—Fluorouracil—pancreatic cancer	0.00113	0.00413	CcSEcCtD
Phentolamine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00112	0.0041	CcSEcCtD
Phentolamine—Pruritus—Erlotinib—pancreatic cancer	0.00112	0.0041	CcSEcCtD
Phentolamine—Nervous system disorder—Irinotecan—pancreatic cancer	0.00111	0.00405	CcSEcCtD
Phentolamine—Diarrhoea—Tamoxifen—pancreatic cancer	0.0011	0.00401	CcSEcCtD
Phentolamine—Abdominal pain—Sunitinib—pancreatic cancer	0.00109	0.00397	CcSEcCtD
Phentolamine—Diarrhoea—Erlotinib—pancreatic cancer	0.00109	0.00396	CcSEcCtD
Phentolamine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00108	0.00395	CcSEcCtD
Phentolamine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00106	0.00388	CcSEcCtD
Phentolamine—Dizziness—Tamoxifen—pancreatic cancer	0.00106	0.00387	CcSEcCtD
Phentolamine—Tachycardia—Fluorouracil—pancreatic cancer	0.00106	0.00386	CcSEcCtD
Phentolamine—Hypotension—Irinotecan—pancreatic cancer	0.00106	0.00386	CcSEcCtD
Phentolamine—Dizziness—Erlotinib—pancreatic cancer	0.00105	0.00383	CcSEcCtD
Phentolamine—Hypotension—Gemcitabine—pancreatic cancer	0.00103	0.00376	CcSEcCtD
Phentolamine—Cardiac disorder—Docetaxel—pancreatic cancer	0.00102	0.00373	CcSEcCtD
Phentolamine—Flushing—Docetaxel—pancreatic cancer	0.00102	0.00373	CcSEcCtD
Phentolamine—Vomiting—Tamoxifen—pancreatic cancer	0.00102	0.00372	CcSEcCtD
Phentolamine—Paraesthesia—Irinotecan—pancreatic cancer	0.00102	0.00371	CcSEcCtD
Phentolamine—Hypotension—Fluorouracil—pancreatic cancer	0.00101	0.0037	CcSEcCtD
Phentolamine—Vomiting—Erlotinib—pancreatic cancer	0.00101	0.00368	CcSEcCtD
Phentolamine—Headache—Tamoxifen—pancreatic cancer	0.00101	0.00367	CcSEcCtD
Phentolamine—Angiopathy—Docetaxel—pancreatic cancer	0.001	0.00365	CcSEcCtD
Phentolamine—Headache—Erlotinib—pancreatic cancer	0.000995	0.00363	CcSEcCtD
Phentolamine—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000993	0.00362	CcSEcCtD
Phentolamine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000991	0.00361	CcSEcCtD
Phentolamine—Asthenia—Sunitinib—pancreatic cancer	0.000987	0.0036	CcSEcCtD
Phentolamine—Arrhythmia—Docetaxel—pancreatic cancer	0.000985	0.00359	CcSEcCtD
Phentolamine—Abdominal pain upper—Epirubicin—pancreatic cancer	0.000982	0.00358	CcSEcCtD
Phentolamine—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000982	0.00358	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000978	0.00357	CcSEcCtD
Phentolamine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000974	0.00355	CcSEcCtD
Phentolamine—Pruritus—Sunitinib—pancreatic cancer	0.000973	0.00355	CcSEcCtD
Phentolamine—Pain—Irinotecan—pancreatic cancer	0.000969	0.00353	CcSEcCtD
Phentolamine—Nausea—Tamoxifen—pancreatic cancer	0.000954	0.00348	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000953	0.00347	CcSEcCtD
Phentolamine—Pain—Gemcitabine—pancreatic cancer	0.000944	0.00344	CcSEcCtD
Phentolamine—Nausea—Erlotinib—pancreatic cancer	0.000944	0.00344	CcSEcCtD
Phentolamine—Diarrhoea—Sunitinib—pancreatic cancer	0.000941	0.00343	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000937	0.00342	CcSEcCtD
Phentolamine—Pain—Fluorouracil—pancreatic cancer	0.000928	0.00338	CcSEcCtD
Phentolamine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000926	0.00338	CcSEcCtD
Phentolamine—Dizziness—Sunitinib—pancreatic cancer	0.000909	0.00332	CcSEcCtD
Phentolamine—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000908	0.00331	CcSEcCtD
Phentolamine—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000908	0.00331	CcSEcCtD
Phentolamine—Angina pectoris—Epirubicin—pancreatic cancer	0.000905	0.0033	CcSEcCtD
Phentolamine—Abdominal pain—Irinotecan—pancreatic cancer	0.000895	0.00327	CcSEcCtD
Phentolamine—Vomiting—Sunitinib—pancreatic cancer	0.000874	0.00319	CcSEcCtD
Phentolamine—Headache—Sunitinib—pancreatic cancer	0.000862	0.00314	CcSEcCtD
Phentolamine—Angina pectoris—Doxorubicin—pancreatic cancer	0.000837	0.00305	CcSEcCtD
Phentolamine—Hypertension—Docetaxel—pancreatic cancer	0.000828	0.00302	CcSEcCtD
Phentolamine—Chest pain—Docetaxel—pancreatic cancer	0.000817	0.00298	CcSEcCtD
Phentolamine—Nausea—Sunitinib—pancreatic cancer	0.000817	0.00298	CcSEcCtD
Phentolamine—Asthenia—Irinotecan—pancreatic cancer	0.000813	0.00296	CcSEcCtD
Phentolamine—Asthenia—Gemcitabine—pancreatic cancer	0.000792	0.00289	CcSEcCtD
Phentolamine—Pruritus—Gemcitabine—pancreatic cancer	0.000781	0.00285	CcSEcCtD
Phentolamine—Diarrhoea—Irinotecan—pancreatic cancer	0.000775	0.00283	CcSEcCtD
Phentolamine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000768	0.0028	CcSEcCtD
Phentolamine—Pruritus—Fluorouracil—pancreatic cancer	0.000768	0.0028	CcSEcCtD
Phentolamine—Tachycardia—Docetaxel—pancreatic cancer	0.000764	0.00279	CcSEcCtD
Phentolamine—Bradycardia—Epirubicin—pancreatic cancer	0.000757	0.00276	CcSEcCtD
Phentolamine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000755	0.00275	CcSEcCtD
Phentolamine—Dizziness—Irinotecan—pancreatic cancer	0.000749	0.00273	CcSEcCtD
Phentolamine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000742	0.00271	CcSEcCtD
Phentolamine—Hypotension—Docetaxel—pancreatic cancer	0.000732	0.00267	CcSEcCtD
Phentolamine—Vomiting—Irinotecan—pancreatic cancer	0.00072	0.00263	CcSEcCtD
Phentolamine—Dizziness—Fluorouracil—pancreatic cancer	0.000717	0.00262	CcSEcCtD
Phentolamine—Headache—Irinotecan—pancreatic cancer	0.00071	0.00259	CcSEcCtD
Phentolamine—Paraesthesia—Docetaxel—pancreatic cancer	0.000703	0.00256	CcSEcCtD
Phentolamine—Vomiting—Gemcitabine—pancreatic cancer	0.000702	0.00256	CcSEcCtD
Phentolamine—Bradycardia—Doxorubicin—pancreatic cancer	0.0007	0.00255	CcSEcCtD
Phentolamine—Headache—Gemcitabine—pancreatic cancer	0.000691	0.00252	CcSEcCtD
Phentolamine—Cardiac disorder—Epirubicin—pancreatic cancer	0.00069	0.00252	CcSEcCtD
Phentolamine—Flushing—Epirubicin—pancreatic cancer	0.00069	0.00252	CcSEcCtD
Phentolamine—Vomiting—Fluorouracil—pancreatic cancer	0.00069	0.00252	CcSEcCtD
Phentolamine—Headache—Fluorouracil—pancreatic cancer	0.00068	0.00248	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000676	0.00247	CcSEcCtD
Phentolamine—Angiopathy—Epirubicin—pancreatic cancer	0.000675	0.00246	CcSEcCtD
Phentolamine—Nausea—Irinotecan—pancreatic cancer	0.000673	0.00245	CcSEcCtD
Phentolamine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.00067	0.00244	CcSEcCtD
Phentolamine—Pain—Docetaxel—pancreatic cancer	0.00067	0.00244	CcSEcCtD
Phentolamine—Arrhythmia—Epirubicin—pancreatic cancer	0.000664	0.00242	CcSEcCtD
Phentolamine—Nausea—Gemcitabine—pancreatic cancer	0.000655	0.00239	CcSEcCtD
Phentolamine—Nausea—Fluorouracil—pancreatic cancer	0.000644	0.00235	CcSEcCtD
Phentolamine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00064	0.00234	CcSEcCtD
Phentolamine—Flushing—Doxorubicin—pancreatic cancer	0.000638	0.00233	CcSEcCtD
Phentolamine—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000638	0.00233	CcSEcCtD
Phentolamine—Angiopathy—Doxorubicin—pancreatic cancer	0.000624	0.00228	CcSEcCtD
Phentolamine—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.00062	0.00226	CcSEcCtD
Phentolamine—Abdominal pain—Docetaxel—pancreatic cancer	0.000619	0.00226	CcSEcCtD
Phentolamine—Arrhythmia—Doxorubicin—pancreatic cancer	0.000615	0.00224	CcSEcCtD
Phentolamine—Asthenia—Docetaxel—pancreatic cancer	0.000562	0.00205	CcSEcCtD
Phentolamine—Hypertension—Epirubicin—pancreatic cancer	0.000559	0.00204	CcSEcCtD
Phentolamine—Pruritus—Docetaxel—pancreatic cancer	0.000554	0.00202	CcSEcCtD
Phentolamine—Chest pain—Epirubicin—pancreatic cancer	0.000551	0.00201	CcSEcCtD
Phentolamine—Diarrhoea—Docetaxel—pancreatic cancer	0.000536	0.00195	CcSEcCtD
Phentolamine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000518	0.00189	CcSEcCtD
Phentolamine—Dizziness—Docetaxel—pancreatic cancer	0.000518	0.00189	CcSEcCtD
Phentolamine—Hypertension—Doxorubicin—pancreatic cancer	0.000517	0.00189	CcSEcCtD
Phentolamine—Tachycardia—Epirubicin—pancreatic cancer	0.000515	0.00188	CcSEcCtD
Phentolamine—Chest pain—Doxorubicin—pancreatic cancer	0.00051	0.00186	CcSEcCtD
Phentolamine—Vomiting—Docetaxel—pancreatic cancer	0.000498	0.00182	CcSEcCtD
Phentolamine—Hypotension—Epirubicin—pancreatic cancer	0.000494	0.0018	CcSEcCtD
Phentolamine—Headache—Docetaxel—pancreatic cancer	0.000491	0.00179	CcSEcCtD
Phentolamine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000479	0.00175	CcSEcCtD
Phentolamine—Tachycardia—Doxorubicin—pancreatic cancer	0.000477	0.00174	CcSEcCtD
Phentolamine—Paraesthesia—Epirubicin—pancreatic cancer	0.000474	0.00173	CcSEcCtD
Phentolamine—Nausea—Docetaxel—pancreatic cancer	0.000465	0.0017	CcSEcCtD
Phentolamine—Hypotension—Doxorubicin—pancreatic cancer	0.000457	0.00167	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000456	0.00166	CcSEcCtD
Phentolamine—Pain—Epirubicin—pancreatic cancer	0.000452	0.00165	CcSEcCtD
Phentolamine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000439	0.0016	CcSEcCtD
Phentolamine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000432	0.00158	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000422	0.00154	CcSEcCtD
Phentolamine—Pain—Doxorubicin—pancreatic cancer	0.000418	0.00152	CcSEcCtD
Phentolamine—Abdominal pain—Epirubicin—pancreatic cancer	0.000418	0.00152	CcSEcCtD
Phentolamine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.0004	0.00146	CcSEcCtD
Phentolamine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000386	0.00141	CcSEcCtD
Phentolamine—Asthenia—Epirubicin—pancreatic cancer	0.000379	0.00138	CcSEcCtD
Phentolamine—Pruritus—Epirubicin—pancreatic cancer	0.000374	0.00136	CcSEcCtD
Phentolamine—Diarrhoea—Epirubicin—pancreatic cancer	0.000361	0.00132	CcSEcCtD
Phentolamine—Asthenia—Doxorubicin—pancreatic cancer	0.000351	0.00128	CcSEcCtD
Phentolamine—Dizziness—Epirubicin—pancreatic cancer	0.000349	0.00127	CcSEcCtD
Phentolamine—Pruritus—Doxorubicin—pancreatic cancer	0.000346	0.00126	CcSEcCtD
Phentolamine—Vomiting—Epirubicin—pancreatic cancer	0.000336	0.00122	CcSEcCtD
Phentolamine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000334	0.00122	CcSEcCtD
Phentolamine—Headache—Epirubicin—pancreatic cancer	0.000331	0.00121	CcSEcCtD
Phentolamine—Dizziness—Doxorubicin—pancreatic cancer	0.000323	0.00118	CcSEcCtD
Phentolamine—Nausea—Epirubicin—pancreatic cancer	0.000314	0.00114	CcSEcCtD
Phentolamine—Vomiting—Doxorubicin—pancreatic cancer	0.000311	0.00113	CcSEcCtD
Phentolamine—Headache—Doxorubicin—pancreatic cancer	0.000306	0.00112	CcSEcCtD
Phentolamine—Nausea—Doxorubicin—pancreatic cancer	0.00029	0.00106	CcSEcCtD
Phentolamine—ADRA2B—Signaling Pathways—HIF1A—pancreatic cancer	3.47e-05	0.000185	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SMAD4—pancreatic cancer	3.46e-05	0.000185	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NOTCH1—pancreatic cancer	3.46e-05	0.000185	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TSC2—pancreatic cancer	3.46e-05	0.000185	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PIK3CD—pancreatic cancer	3.45e-05	0.000184	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—AKT1—pancreatic cancer	3.44e-05	0.000184	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—CXCL8—pancreatic cancer	3.42e-05	0.000183	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CG—pancreatic cancer	3.41e-05	0.000182	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TERT—pancreatic cancer	3.39e-05	0.000181	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—APOE—pancreatic cancer	3.39e-05	0.000181	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CG—pancreatic cancer	3.38e-05	0.000181	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—NRAS—pancreatic cancer	3.38e-05	0.000181	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HES1—pancreatic cancer	3.38e-05	0.000181	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EGF—pancreatic cancer	3.34e-05	0.000179	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TERT—pancreatic cancer	3.33e-05	0.000178	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—KDR—pancreatic cancer	3.32e-05	0.000177	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	3.31e-05	0.000177	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PPARG—pancreatic cancer	3.29e-05	0.000176	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HIF1A—pancreatic cancer	3.24e-05	0.000173	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—PIK3CB—pancreatic cancer	3.24e-05	0.000173	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TSC2—pancreatic cancer	3.23e-05	0.000173	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SMAD4—pancreatic cancer	3.22e-05	0.000172	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—AKT1—pancreatic cancer	3.21e-05	0.000172	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—PIK3CA—pancreatic cancer	3.19e-05	0.000171	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HIF1A—pancreatic cancer	3.19e-05	0.00017	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—CXCL8—pancreatic cancer	3.18e-05	0.00017	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TSC2—pancreatic cancer	3.18e-05	0.00017	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—APOE—pancreatic cancer	3.16e-05	0.000169	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NFKBIA—pancreatic cancer	3.15e-05	0.000169	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HES1—pancreatic cancer	3.14e-05	0.000168	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NOTCH1—pancreatic cancer	3.12e-05	0.000167	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—APOE—pancreatic cancer	3.11e-05	0.000166	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CXCL8—pancreatic cancer	3.11e-05	0.000166	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—KDR—pancreatic cancer	3.1e-05	0.000166	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—TP53—pancreatic cancer	3.09e-05	0.000165	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—EGFR—pancreatic cancer	3.08e-05	0.000165	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—APOE—pancreatic cancer	3.07e-05	0.000164	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CG—pancreatic cancer	3.05e-05	0.000163	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—NRAS—pancreatic cancer	3.05e-05	0.000163	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—KDR—pancreatic cancer	3.05e-05	0.000163	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EGF—pancreatic cancer	3.02e-05	0.000161	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PIK3CB—pancreatic cancer	3.01e-05	0.000161	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CD—pancreatic cancer	3e-05	0.00016	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CD—pancreatic cancer	2.97e-05	0.000159	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TERT—pancreatic cancer	2.96e-05	0.000158	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—HRAS—pancreatic cancer	2.95e-05	0.000158	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NFKBIA—pancreatic cancer	2.95e-05	0.000157	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.95e-05	0.000157	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NOTCH1—pancreatic cancer	2.92e-05	0.000156	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—KRAS—pancreatic cancer	2.91e-05	0.000156	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NFKBIA—pancreatic cancer	2.9e-05	0.000155	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	2.89e-05	0.000154	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NOTCH1—pancreatic cancer	2.87e-05	0.000153	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CG—pancreatic cancer	2.85e-05	0.000153	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—NRAS—pancreatic cancer	2.85e-05	0.000153	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HIF1A—pancreatic cancer	2.83e-05	0.000151	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TSC2—pancreatic cancer	2.82e-05	0.000151	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EGF—pancreatic cancer	2.82e-05	0.000151	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CG—pancreatic cancer	2.81e-05	0.00015	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—NRAS—pancreatic cancer	2.81e-05	0.00015	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—EGFR—pancreatic cancer	2.78e-05	0.000149	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EGF—pancreatic cancer	2.78e-05	0.000148	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	2.77e-05	0.000148	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	2.76e-05	0.000148	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	2.75e-05	0.000147	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	2.71e-05	0.000145	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CD—pancreatic cancer	2.69e-05	0.000144	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—PIK3CA—pancreatic cancer	2.68e-05	0.000143	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PPARG—pancreatic cancer	2.68e-05	0.000143	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.66e-05	0.000142	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	2.63e-05	0.000141	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—KRAS—pancreatic cancer	2.63e-05	0.000141	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	2.62e-05	0.00014	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CB—pancreatic cancer	2.61e-05	0.00014	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—AKT1—pancreatic cancer	2.61e-05	0.000139	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—EGFR—pancreatic cancer	2.6e-05	0.000139	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CB—pancreatic cancer	2.59e-05	0.000139	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTGS2—pancreatic cancer	2.59e-05	0.000138	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	2.58e-05	0.000138	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	2.57e-05	0.000137	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—EGFR—pancreatic cancer	2.56e-05	0.000137	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	2.55e-05	0.000136	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	2.52e-05	0.000134	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CD—pancreatic cancer	2.51e-05	0.000134	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	2.49e-05	0.000133	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	2.49e-05	0.000133	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CXCL8—pancreatic cancer	2.49e-05	0.000133	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.48e-05	0.000133	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—HRAS—pancreatic cancer	2.48e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CD—pancreatic cancer	2.47e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	2.47e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—KRAS—pancreatic cancer	2.46e-05	0.000131	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.45e-05	0.000131	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	2.44e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—KRAS—pancreatic cancer	2.42e-05	0.000129	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—PIK3CA—pancreatic cancer	2.42e-05	0.000129	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—AKT1—pancreatic cancer	2.41e-05	0.000129	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	2.39e-05	0.000128	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CASP3—pancreatic cancer	2.38e-05	0.000127	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	2.37e-05	0.000127	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CB—pancreatic cancer	2.34e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCND1—pancreatic cancer	2.32e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	2.32e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	2.32e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CTNNB1—pancreatic cancer	2.3e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	2.29e-05	0.000122	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	2.27e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTEN—pancreatic cancer	2.26e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—PIK3CA—pancreatic cancer	2.26e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MMP9—pancreatic cancer	2.25e-05	0.00012	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CXCL8—pancreatic cancer	2.25e-05	0.00012	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PTEN—pancreatic cancer	2.24e-05	0.00012	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—HRAS—pancreatic cancer	2.23e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—PIK3CA—pancreatic cancer	2.22e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	2.19e-05	0.000117	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CB—pancreatic cancer	2.19e-05	0.000117	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—AKT1—pancreatic cancer	2.19e-05	0.000117	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—AKT1—pancreatic cancer	2.17e-05	0.000116	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.17e-05	0.000116	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CASP3—pancreatic cancer	2.15e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	2.15e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	2.15e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	2.12e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	2.11e-05	0.000113	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTGS2—pancreatic cancer	2.1e-05	0.000112	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CXCL8—pancreatic cancer	2.1e-05	0.000112	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCND1—pancreatic cancer	2.1e-05	0.000112	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—HRAS—pancreatic cancer	2.09e-05	0.000112	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—SRC—pancreatic cancer	2.08e-05	0.000111	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	2.08e-05	0.000111	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	2.07e-05	0.000111	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	2.05e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	2.04e-05	0.000109	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	2.03e-05	0.000109	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	2.03e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—VEGFA—pancreatic cancer	2.02e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	2.02e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.02e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	2.01e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—STAT3—pancreatic cancer	2e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NRAS—pancreatic cancer	2e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	2e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	1.99e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	1.98e-05	0.000106	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	1.97e-05	0.000105	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.97e-05	0.000105	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	1.96e-05	0.000105	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.94e-05	0.000104	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	1.93e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.91e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	1.91e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	1.9e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	1.89e-05	0.000101	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	1.88e-05	0.0001	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	1.87e-05	0.0001	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	1.86e-05	9.95e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	1.86e-05	9.94e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	1.86e-05	9.93e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	1.84e-05	9.85e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	1.84e-05	9.82e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTEN—pancreatic cancer	1.84e-05	9.81e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.83e-05	9.8e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	1.83e-05	9.76e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	1.82e-05	9.75e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	1.82e-05	9.73e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	1.81e-05	9.7e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	1.81e-05	9.67e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	1.8e-05	9.64e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.78e-05	9.49e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	1.77e-05	9.48e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	1.76e-05	9.4e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	1.75e-05	9.36e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	1.72e-05	9.22e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	1.72e-05	9.19e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	1.71e-05	9.15e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	1.71e-05	9.12e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	1.71e-05	9.12e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	1.7e-05	9.06e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.69e-05	9.06e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	1.69e-05	9.03e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	1.69e-05	9.01e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	1.68e-05	8.98e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	1.68e-05	8.98e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	1.68e-05	8.96e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	1.66e-05	8.89e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	1.66e-05	8.88e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	1.66e-05	8.87e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	1.65e-05	8.83e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.65e-05	8.81e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	1.64e-05	8.79e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	1.63e-05	8.73e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	1.61e-05	8.61e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	1.59e-05	8.52e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	1.59e-05	8.5e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.58e-05	8.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.57e-05	8.42e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	1.57e-05	8.39e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	1.57e-05	8.37e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	1.55e-05	8.3e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	1.55e-05	8.26e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	1.54e-05	8.25e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	1.54e-05	8.24e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	1.54e-05	8.21e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	1.53e-05	8.2e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	1.53e-05	8.19e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	1.53e-05	8.17e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	1.51e-05	8.08e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	1.5e-05	8e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	1.49e-05	7.97e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	1.48e-05	7.9e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	1.47e-05	7.88e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	1.46e-05	7.82e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	1.45e-05	7.75e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	1.43e-05	7.63e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.43e-05	7.63e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	1.42e-05	7.61e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	1.39e-05	7.41e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	1.38e-05	7.38e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	1.37e-05	7.34e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	1.37e-05	7.34e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	1.37e-05	7.32e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	1.37e-05	7.32e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	1.34e-05	7.18e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.33e-05	7.12e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	1.32e-05	7.06e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.31e-05	7.01e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AKT1—pancreatic cancer	1.3e-05	6.96e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	1.29e-05	6.92e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	1.29e-05	6.9e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	1.29e-05	6.89e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	1.28e-05	6.82e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	1.27e-05	6.8e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	1.27e-05	6.78e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	1.27e-05	6.78e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	1.25e-05	6.67e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	1.23e-05	6.59e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	1.21e-05	6.49e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	1.18e-05	6.3e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	1.17e-05	6.23e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.17e-05	6.23e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	1.13e-05	6.02e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	1.09e-05	5.82e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.08e-05	5.79e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	1.08e-05	5.76e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	1.07e-05	5.73e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AKT1—pancreatic cancer	1.06e-05	5.65e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	1.05e-05	5.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	1e-05	5.35e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	9.52e-06	5.09e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	8.84e-06	4.73e-05	CbGpPWpGaD
